ABBISKO CAYMAN DL-00001 - Asset Resilience Ratio
ABBISKO CAYMAN DL-00001 (8ZD) has an Asset Resilience Ratio of 57.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore ABBISKO CAYMAN DL-00001 total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ABBISKO CAYMAN DL-00001's Asset Resilience Ratio has changed over time. See 8ZD net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ABBISKO CAYMAN DL-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of ABBISKO CAYMAN DL-00001.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.35 Billion | 57.39% |
| Total Liquid Assets | €1.35 Billion | 57.39% |
Asset Resilience Insights
- Very High Liquidity: ABBISKO CAYMAN DL-00001 maintains exceptional liquid asset reserves at 57.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABBISKO CAYMAN DL-00001 Industry Peers by Asset Resilience Ratio
Compare ABBISKO CAYMAN DL-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for ABBISKO CAYMAN DL-00001 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ABBISKO CAYMAN DL-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.39% | €1.35 Billion ≈ $1.58 Billion |
€2.35 Billion ≈ $2.75 Billion |
-21.86pp |
| 2024-12-31 | 79.25% | €1.67 Billion ≈ $1.95 Billion |
€2.11 Billion ≈ $2.46 Billion |
+13.69pp |
| 2023-12-31 | 65.56% | €1.39 Billion ≈ $1.62 Billion |
€2.12 Billion ≈ $2.47 Billion |
-3.16pp |
| 2022-12-31 | 68.72% | €1.71 Billion ≈ $2.00 Billion |
€2.49 Billion ≈ $2.91 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal tri… Read more